Image_2_Use of tobacco, nicotine and cannabis products among students in Switzerland.png

IntroductionMost people who smoke cigarettes begin in their teens and teens may also be attracted to new tobacco, nicotine, and cannabis products. We describe use prevalence among upper-secondary school students in Switzerland, including daily use, of tobacco, nicotine, and cannabis products.MethodsWe invited secondary school students (age 15 to 21) in two Swiss cantons to take an online survey between October 2021 and February 2022. The survey collected demographic information and asked how frequently they used tobacco products (cigarettes in commercial packages, self-rolled cigarettes, hookahs, pipes, cigars and cigarillos, tobacco heating systems, snus, snuff), non-tobacco nicotine products (nicotine pouches, e-cigarettes with and without nicotine), and cannabis products (smoking with and without tobacco, cannabis vaping). Answers were scored on a Likert scale (no use in past month, less than weekly, weekly but not daily, daily use, prefer not to say), then tabulated and reported as descriptive statistics.ResultsOf 32,614 students in the schools we contacted, 9,515 (29.2%) completed the survey; 49.5% identified as female and 48.4% as male; 9.5% were under 16, 47% were 16–17, 27.5% were 18–19, and 16% were over 19. Reported daily use was most frequent for tobacco cigarettes in commercial packages (14.2%), snus (4.1%) and cannabis smoking with tobacco (3.6%). Most participants (54.8%) reported they had used at least one product at least once within the last month.ConclusionStudents who used a product were most likely to smoke cigarettes, but many regularly used new tobacco, nicotine and cannabis products, though use frequency varies.</p

Image_3_Use of tobacco, nicotine and cannabis products among students in Switzerland.png

IntroductionMost people who smoke cigarettes begin in their teens and teens may also be attracted to new tobacco, nicotine, and cannabis products. We describe use prevalence among upper-secondary school students in Switzerland, including daily use, of tobacco, nicotine, and cannabis products.MethodsWe invited secondary school students (age 15 to 21) in two Swiss cantons to take an online survey between October 2021 and February 2022. The survey collected demographic information and asked how frequently they used tobacco products (cigarettes in commercial packages, self-rolled cigarettes, hookahs, pipes, cigars and cigarillos, tobacco heating systems, snus, snuff), non-tobacco nicotine products (nicotine pouches, e-cigarettes with and without nicotine), and cannabis products (smoking with and without tobacco, cannabis vaping). Answers were scored on a Likert scale (no use in past month, less than weekly, weekly but not daily, daily use, prefer not to say), then tabulated and reported as descriptive statistics.ResultsOf 32,614 students in the schools we contacted, 9,515 (29.2%) completed the survey; 49.5% identified as female and 48.4% as male; 9.5% were under 16, 47% were 16–17, 27.5% were 18–19, and 16% were over 19. Reported daily use was most frequent for tobacco cigarettes in commercial packages (14.2%), snus (4.1%) and cannabis smoking with tobacco (3.6%). Most participants (54.8%) reported they had used at least one product at least once within the last month.ConclusionStudents who used a product were most likely to smoke cigarettes, but many regularly used new tobacco, nicotine and cannabis products, though use frequency varies.</p

Image_1_Use of tobacco, nicotine and cannabis products among students in Switzerland.png

IntroductionMost people who smoke cigarettes begin in their teens and teens may also be attracted to new tobacco, nicotine, and cannabis products. We describe use prevalence among upper-secondary school students in Switzerland, including daily use, of tobacco, nicotine, and cannabis products.MethodsWe invited secondary school students (age 15 to 21) in two Swiss cantons to take an online survey between October 2021 and February 2022. The survey collected demographic information and asked how frequently they used tobacco products (cigarettes in commercial packages, self-rolled cigarettes, hookahs, pipes, cigars and cigarillos, tobacco heating systems, snus, snuff), non-tobacco nicotine products (nicotine pouches, e-cigarettes with and without nicotine), and cannabis products (smoking with and without tobacco, cannabis vaping). Answers were scored on a Likert scale (no use in past month, less than weekly, weekly but not daily, daily use, prefer not to say), then tabulated and reported as descriptive statistics.ResultsOf 32,614 students in the schools we contacted, 9,515 (29.2%) completed the survey; 49.5% identified as female and 48.4% as male; 9.5% were under 16, 47% were 16–17, 27.5% were 18–19, and 16% were over 19. Reported daily use was most frequent for tobacco cigarettes in commercial packages (14.2%), snus (4.1%) and cannabis smoking with tobacco (3.6%). Most participants (54.8%) reported they had used at least one product at least once within the last month.ConclusionStudents who used a product were most likely to smoke cigarettes, but many regularly used new tobacco, nicotine and cannabis products, though use frequency varies.</p

Data_Sheet_1_Use of tobacco, nicotine and cannabis products among students in Switzerland.pdf

IntroductionMost people who smoke cigarettes begin in their teens and teens may also be attracted to new tobacco, nicotine, and cannabis products. We describe use prevalence among upper-secondary school students in Switzerland, including daily use, of tobacco, nicotine, and cannabis products.MethodsWe invited secondary school students (age 15 to 21) in two Swiss cantons to take an online survey between October 2021 and February 2022. The survey collected demographic information and asked how frequently they used tobacco products (cigarettes in commercial packages, self-rolled cigarettes, hookahs, pipes, cigars and cigarillos, tobacco heating systems, snus, snuff), non-tobacco nicotine products (nicotine pouches, e-cigarettes with and without nicotine), and cannabis products (smoking with and without tobacco, cannabis vaping). Answers were scored on a Likert scale (no use in past month, less than weekly, weekly but not daily, daily use, prefer not to say), then tabulated and reported as descriptive statistics.ResultsOf 32,614 students in the schools we contacted, 9,515 (29.2%) completed the survey; 49.5% identified as female and 48.4% as male; 9.5% were under 16, 47% were 16–17, 27.5% were 18–19, and 16% were over 19. Reported daily use was most frequent for tobacco cigarettes in commercial packages (14.2%), snus (4.1%) and cannabis smoking with tobacco (3.6%). Most participants (54.8%) reported they had used at least one product at least once within the last month.ConclusionStudents who used a product were most likely to smoke cigarettes, but many regularly used new tobacco, nicotine and cannabis products, though use frequency varies.</p

Documented Treatment at Discharge for participants hospitalized for an acute coronary syndrome in 4 academic centers Switzerland from Sept 2009 to October 2010.

<p>DAPT: Dual antiplatelet therapy; N, number of participants; STEMI: ST-segment elevation myocardial infarction; NP: non-prescription; NSTEMI: Non ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction.</p><p>* Concomitant prescription at discharge unless contra-indicated or not indicated for aspirin, clopidogrel/prasugrel or ticagrelor if PCI-stent treatment, beta-blocker, statin, ACEI if EF≤40%. When participants transferred to peripheral hospital, beta-blocker and ACEI/ATII coded as not applicable.</p><p>Prescription rates according to guidelines taking into account reported indications reasons for not prescribing medication at discharge.</p

Documented reasons for not prescribing recommended cardiovascular medication at discharge.

<p>ACEI: Angiotensin Converting Enzyme Inhibitor; ATII: Angiotensin II receptor blockers; NA: Not applicable; NR: not reported.</p>†<p>6 patients discharged home directly and who had “to be introduced later” as the reason for not prescription were coded as not having been prescribed the recommended medication.</p

Percent of participants with recommended treatment at discharge taking into account reported reasons for non-prescription.

<p>Abbreviations: P2Y12 inhibitors: clopidogrel, prasugrel or ticagrelor; ACEI/ATII : Angiotensin converting enzyme inhibitor/angiotensin II receptor blockers. * P2Y12 inhibitors if PCI-stent treatment (n = 1066). ** ACEI/ATII inhibitors if left ventricular ejection fraction (LVEF) ≤40% (n = 220).</p

Baseline characteristics of the participants to the study hospitalized for an acute coronary syndrome in 4 academic centers in Switzerland from September 2009 to October 2010.

<p>N, number of participants; BMI, body mass index; CABG, coronary artery by-pass graft; CHD, coronary heart disease; CR: cardiac rehabilitation; LVEF: Left ventricular ejection fraction; CHF, congestive heart failure; NSTEMI: Non ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; Q1: first quartile; Q3; third quartile; STEMI: ST-segment elevation myocardial infarction.</p><p>*38 participants with missing information on education status or who refused to disclose their education status.</p>†<p>Previous hypercholesterolemia, hypertension and diabetes based on self-report by patients or previous treatment by preventive medication specific to the hypercholesterolemia, hypertension or diabetes.</p

Participant characteristics.

<p>Participant characteristics.</p

Ft4 measures when TSH falls within the normal range.

<p>FT4 measures when TSH falls within the normal range (0.45–4.5 mU/L); 85% of abnormal fT4 measures are within 2 pmol/l (dashed lines) of the reference range (11.2 to 20.8 pmol/L, solid lines). Abbreviations: Free Thyroxine (fT4) Thyroid-Stimulating Hormone (TSH).</p